The DOI matches its Crossref record.
Principles and practice of HIV‐protease inhibitor pharmacoenhancement
Abstract
Continually maintaining maximally suppressive drug concentrations represents a key defence against the emergence of resistance. If drug levels fall and replication occurs, the opportunity for mutant virus to be selected occurs. It has been increasingly recognized that variability in the pharmacokinetics of antiretrovirals, particularly protease inhibitors (PIs), means that drug exposure is not always optimal, giving the virus a chance to replicate. A significant number of patients receiving PIs two or three times daily will have trough (C trough or C min) plasma concentrations, which are close to, or below, the plasma protein binding‐corrected inhibitory concentration (IC 50 or IC 95) during the dosing interval. It is primarily in this context that therapeutic drug monitoring of PIs has been proposed as an aid to patient management, to ensure that patients maintain adequate drug concentrations throughout the dosing interval. Ideally, an antiretroviral drug will have a pharmacokinetic (PK) profile that maintains drug levels well above the viral inhibitory concentration throughout the entire dosing interval. Beneficial drug–drug interactions have been shown to improve PI pharmacokinetics. Ritonavir (RTV) inhibits the key enzymes that limit the bioavailability or speed the metabolism of other PIs. It is therefore increasingly used for boosting and maintaining PI plasma concentrations. At low (100 mg twice a day) doses it acts as a pharmacoenhancer of indinavir (IDV), amprenavir, saquinavir, lopinavir and to a more limited degree nelfinavir. Using a pharmacoenhancer with a PI results in increased exposure to the PI, higher C min levels, and in most cases prolonged elimination half‐lives. The long‐term clinical benefits of PK enhancing are unknown as are the long‐term toxicities, although the incidence of nephrolithiasis with IDV appears increased when IDV is combined with low‐dose RTV in HIV‐infected patients. Head‐to‐head clinical comparisons of boosted PI regimens will help answer some of the questions that remain with regard to PK enhancement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lopinavir/Ritonavir: A Review of its Use in the Management of HIV Infection
Cvetkovic, R. S., & Goa, K. L. (2003) · Drugs · doi:10.2165/00003495-200363080-00004 · Cited by 436
Zeldin, R. K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh029 · Cited by 316
Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes
Wang, H., & LeCluyse, E. L. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00003 · Cited by 278
Arend, C., Brandmann, M., & Dringen, R. (2013) · Neurochemical Research · doi:10.1007/s11064-013-0971-x · Cited by 21
Metadata
- Authors
- Moyle, G., & Back, D.
- Venue
- HIV Medicine
- Publisher
- Wiley
- Published
- 2001-04
- Volume
- 2
- Issue
- 2
- Pages
- 105-113
- ISSN
- 1464-2662 (ISSN-L)
- 1468-1293
- OpenAlex
- W2067274937
- Cited by
- 177
- References
- 0
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Principles and practice of HIV‐protease inhibitor pharmacoenhancement. https://app.cochat.ai/papers/10.1046/j.1468-1293.2001.00063.x
- The paper
- Moyle, G., & Back, D. (2001). Principles and practice of HIV‐protease inhibitor pharmacoenhancement. HIV Medicine. https://doi.org/10.1046/j.1468-1293.2001.00063.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.